🔎 Trials Near Me

Akèy › Leksemi biphenotipik egi › North Carolina

Etid klinik pou Leksemi biphenotipik egi nan North Carolina

11 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan North Carolina.

Vil nan North Carolina

Tèks ofisyèl etid la (Anglè)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • ak 2 plis
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Duke University Medical Center, Durham
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • ak 4 plis
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • ak 4 plis
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

  • Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Ap rekriteFaz 2
Laj 1 a 18 · Tout sèks · Mizajou Aug 10, 2026 · NCT06390319

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

  • Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Ap rekriteFaz 4
Laj 1 a 18 · Tout sèks · Mizajou Jul 14, 2026 · NCT06289673

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • ak 4 plis
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825

A Study of Revumenib and Mezigdomide in People With Leukemia

  • University of North Carolina (Data Collection Only), Chapel Hill
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT07356154

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Carolina-Levine Children's Hospital, Charlotte
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.